Overview
Rakuten Medical, a global biotechnology company, has closed a $100 million Series F financing round, which includes $70 million in new capital and $30 million in converted notes. This funding will support the advancement of its investigational photoimmunotherapy drug, ASP-1929, aimed at securing U.S. regulatory approval and expanding clinical trials for head and neck cancer. The round was led by Taiax Life Science Fund and included major Japanese and Taiwanese investors, reflecting strong confidence in the company's innovative technology.
Products
Loading...
Recent Deals
Investors: Taiax Life Science Fund
Rakuten Medical, a global biotechnology company, has closed a $100 million Series F financing round, which includes $70 million in new capital and $30 million in converted notes. This funding will support the advancement of its investigational photoimmunotherapy drug, ASP-1929, aimed at securing U.S. regulatory approval and expanding clinical trials for head and neck cancer. The round was led by Taiax Life Science Fund and included major Japanese and Taiwanese investors, reflecting strong confidence in the company's innovative technology.